朗格维他在预防复发性阿弗他溃疡中的作用。

LongoVital in the prevention of recurrent aphthous ulceration.

作者信息

Pedersen A, Hougen H P, Klausen B, Winther K

机构信息

Department of Dentistry, University Hospital (Rigshospitalet), Copenhagen, Denmark.

出版信息

J Oral Pathol Med. 1990 Sep;19(8):371-5. doi: 10.1111/j.1600-0714.1990.tb00862.x.

DOI:10.1111/j.1600-0714.1990.tb00862.x

PMID:2250227

Abstract

LongoVital (LV) (DK. Reg. No. 5178/75) is a herbal based tablet enriched with recommended doses of vitamins. The present study was undertaken to investigate prevention of recurrent aphthous ulceration (RAU) during 6 months' daily intake of LV as compared with placebo in a double-blind, randomized clinical, cross-over 1-yr study. The population comprised 29 otherwise healthy minor RAU patients (18 F, 11 M), mean age 36 (18-67), with an estimated average number of recurrences the previous year of 12.8 (3-30). The number of recurrences was significantly reduced on LV the latter 4 of the 6 months (P less than 0.01) where 31% were totally free of recurrences. Subjective all-over evaluation of treatment period was significantly in favor of LV. LV induced no adverse reactions and is the first harmless systemic treatment which has proved better than placebo in the prevention of RAU.

摘要

朗格维他（LV）（丹麦注册号5178/75）是一种富含推荐剂量维生素的草本片剂。本研究旨在通过一项为期1年的双盲、随机临床交叉研究，对比在每日服用LV 6个月期间与服用安慰剂相比，复发性阿弗他溃疡（RAU）的预防情况。研究对象包括29名其他方面健康的轻度RAU患者（18名女性，11名男性），平均年龄36岁（18 - 67岁），估计前一年的复发平均次数为12.8次（3 - 30次）。在6个月的后4个月，服用LV时复发次数显著减少（P小于0.01），其中31%完全没有复发。对治疗期的总体主观评价明显有利于LV。LV未引起不良反应，是第一种在预防RAU方面被证明优于安慰剂的无害全身治疗方法。